response

Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy…

5 months ago

Prime Success Responds to Sinovac Biotechs False and Misleading Claims

For More Information, Visit www.SaveSinovac.comHONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder…

5 months ago

LifeLabs Supports Communities Impacted by Saskatchewan Wildfires with $15,000 Donation

Toronto, ON, June 10, 2025 (GLOBE NEWSWIRE) -- In response to the devastating wildfires affecting communities across Saskatchewan, LifeLabs is…

6 months ago

Quantum Metal Recovery Inc. Responds to Besra Gold’s ASX Announcement, Initiates Legal Proceedings in Ontario

PENANG, Malaysia, June 6, 2025 /PRNewswire/ -- Quantum Metal Recovery Inc. (QMRI), the largest shareholder of Besra Gold Inc. (Besra),…

6 months ago

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign

MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and…

6 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

6 months ago
Show previous Posts